-
[show abstract]
[hide abstract]
ABSTRACT: Transient receptor potential subfamily V, member 1 (TRPV1) is a nonselective cation channel expressed in both the peripheral and central nervous systems (CNS). TRPV1 protein levels in rat tissues were determined under normal and pain states using enzyme-linked immunosorbent assay. In naive rats, brain TRPV1 protein concentrations ranged from 1.5 to 4 ng/mg in hippocampus, cortex, hypothalamus, and cerebellum. Rat spinal cord TRPV1 protein levels were 40-50 ng/mg in L1-L5 of the lumbar regions, but increased to 97 ± 9.3 ng/mg toward the end of the lumbar region (L6-S1). In the complete Freund's adjuvant (CFA)-induced inflammatory pain model, TRPV1 protein level significantly increased on both the contralateral (36.5 %, p < 0.05) and ipsilateral (31.4 %, p < 0.05) L4-L6 dorsal root ganglia (DRG). TRPV1 protein levels also increased 33.3 % (p < 0.05) on the ipsilateral sciatic nerve, but no significant change in the lumbar spinal cord of CFA rats. In the monoiodoacetate-induced rat knee joint pain model, TRPV1 protein level was significantly reduced in the ipsilateral L3-L5 DRG (33.3 %, p < 0.01), no significant difference was detected in the lumbar region of the spinal cord. Quantitative determination of TRPV1 protein levels may help to elucidate the TRPV1 physiological roles and regulatory mechanisms in various pain states.
Journal of Molecular Neuroscience 07/2012; · 2.50 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The transient receptor potential vanilloid receptor type 1 (TRPV1) is a non-selective cation channel expressed in both the peripheral and the central nervous systems. To quantitatively determine TRPV1 protein levels in native rat tissues, novel monoclonal antibodies were raised against full-length recombinant human TRPV1 protein and utilized to develop a sandwich ELISA assay. Monoclonal antibody 10E3-1A2 specifically recognized TRPV1 protein and the recognition epitope was determined to reside in amino acids 45-58 of human and rat TRPV1. Using the TRPV1 polyclonal antibody ABRK4 as the capturing antibody and the monoclonal antibody 10E3-1A2 as the detection antibody, a sandwich ELISA that detected both human and rat TRPV1 protein was established. Recombinant human TRPV1 heterologously expressed in mammalian HEK293-F cells, which showed high ligand-binding affinity, was purified by TRPV1 monoclonal antibody affinity chromatography and used as protein standard to quantify TRPV1 protein levels. This ELISA detected TRPV1 protein as low as 1.5ng/ml (15pM), and was able to determine TRPV1 protein levels in native rat tissues such as DRG and spinal cord. This is the first TRPV1 sandwich ELISA that determines the abundance of TRPV1 protein in different tissues. It provides a powerful tool to quantify changes of TRPV1 protein levels in pathological states.
Journal of neuroscience methods 09/2011; 200(2):144-52. · 2.30 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Synthesis and biological evaluation of a novel class of substituted N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine derivatives resulted in the identification of potent P2X(7) antagonists. These compounds were assayed for activity at both the human and rat P2X(7) receptors. On the benzyl moiety, a variety of functional groups were tolerated, including both electron-withdrawing and electron-donating substituents. Ortho-substitution on the benzyl group provided the greatest potency. The ortho-substituted analogs showed approximately 2.5-fold greater potency at human compared to rat P2X(7) receptors. Compounds 12 and 38 displayed hP2X(7)pIC(50)s>7.8 with less than 2-fold difference in potency at the rP2X(7).
Bioorganic & medicinal chemistry letters 06/2011; 21(11):3297-300. · 2.65 Impact Factor
-
Robert G Schmidt,
Erol K Bayburt,
Steven P Latshaw,
John R Koenig,
Jerome F Daanen,
Heath A McDonald,
Bruce R Bianchi,
Chengmin Zhong,
Shailen Joshi,
Prisca Honore,
Kennan C Marsh,
Chih-Hung Lee, Connie R Faltynek,
Arthur Gomtsyan
[show abstract]
[hide abstract]
ABSTRACT: Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.
Bioorganic & medicinal chemistry letters 03/2011; 21(5):1338-41. · 2.65 Impact Factor
-
Jun Chen,
Shailen K Joshi,
Stanley DiDomenico,
Richard J Perner,
Joe P Mikusa,
Donna M Gauvin,
Jason A Segreti,
Ping Han,
Xu-Feng Zhang,
Wende Niforatos, [......],
Chengmin Zhong,
Gricelda H Simler,
Heath A McDonald,
Robert G Schmidt,
Steve P McGaraughty,
Katharine L Chu, Connie R Faltynek,
Michael E Kort,
Regina M Reilly,
Philip R Kym
[show abstract]
[hide abstract]
ABSTRACT: Despite the increasing interest in TRPA1 channel as a pain target, its role in cold sensation and body temperature regulation is not clear; the efficacy and particularly side effects resulting from channel blockade remain poorly understood. Here we use a potent, selective, and bioavailable antagonist to address these issues. A-967079 potently blocks human (IC(50): 51 nmol/L, electrophysiology, 67 nmol/L, Ca(2+) assay) and rat TRPA1 (IC(50): 101 nmol/L, electrophysiology, 289 nmol/L, Ca(2+) assay). It is >1000-fold selective over other TRP channels, and is >150-fold selective over 75 other ion channels, enzymes, and G-protein-coupled receptors. Oral dosing of A-967079 produces robust drug exposure in rodents, and exhibits analgesic efficacy in allyl isothiocyanate-induced nocifensive response and osteoarthritic pain in rats (ED(50): 23.2 mg/kg, p.o.). A-967079 attenuates cold allodynia produced by nerve injury but does not alter noxious cold sensation in naive animals, suggesting distinct roles of TRPA1 in physiological and pathological states. Unlike TRPV1 antagonists, A-967079 does not alter body temperature. It also does not produce locomotor or cardiovascular side effects. Collectively, these data provide novel insights into TRPA1 function and suggest that the selective TRPA1 blockade may present a viable strategy for alleviating pain without untoward side effects.
Pain 03/2011; 152(5):1165-72. · 5.78 Impact Factor
-
Michael E Kort,
Robert N Atkinson,
James B Thomas,
Irene Drizin,
Matthew S Johnson,
Matthew A Secrest,
Robert J Gregg,
Marc J C Scanio,
Lei Shi,
Ahmed H Hakeem, [......],
Shailen Joshi,
Prisca Honore,
Rosemarie Roeloffs,
Stephen Werness,
Brett Antonio,
Kennan C Marsh, Connie R Faltynek,
Douglas S Krafte,
Michael F Jarvis,
Brian E Marron
[show abstract]
[hide abstract]
ABSTRACT: A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Na(v)1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain.
Bioorganic & medicinal chemistry letters 11/2010; 20(22):6812-5. · 2.65 Impact Factor
-
Xu-Feng Zhang,
Char-Chang Shieh,
Mark L Chapman,
Mark A Matulenko,
Ahmed H Hakeem,
Robert N Atkinson,
Michael E Kort,
Brian E Marron,
Shailen Joshi,
Prisca Honore, Connie R Faltynek,
Douglas S Krafte,
Michael F Jarvis
[show abstract]
[hide abstract]
ABSTRACT: Activation of sodium channels is essential to action potential generation and propagation. Recent genetic and pharmacological evidence indicates that activation of Na(v)1.8 channels contributes to chronic pain. Herein, we describe the identification of a novel series of structurally related pyridine derivatives as potent Na(v)1.8 channel blockers. A-887826 exemplifies this series and potently (IC(50)=11nM) blocked recombinant human Na(v)1.8 channels. A-887826 was approximately 3 fold less potent to block Na(v)1.2, approximately 10 fold less potent to block tetrodotoxin-sensitive sodium (TTX-S Na(+)) currents and was >30 fold less potent to block Na(V)1.5 channels. A-887826 potently blocked tetrodotoxin-resistant sodium (TTX-R Na(+)) currents (IC(50)=8nM) from small diameter rat dorsal root ganglion (DRG) neurons in a voltage-dependent fashion. A-887826 effectively suppressed evoked action potential firing when DRG neurons were held at depolarized potentials and reversibly suppressed spontaneous firing in small diameter DRG neurons from complete Freund's adjuvant inflamed rats. Following oral administration, A-887826 significantly attenuated tactile allodynia in a rat neuropathic pain model. Further characterization of TTX-R current block in rat DRG neurons demonstrated that A-887826 (100nM) shifted the mid-point of voltage-dependent inactivation of TTX-R currents by approximately 4mV without affecting voltage-dependent activation and did not exhibit frequency-dependent inhibition. The present data demonstrate that A-887826 is a structurally novel and potent Na(v)1.8 blocker that inhibits rat DRG TTX-R currents in a voltage-, but not frequency-dependent fashion. The ability of this structurally novel Na(v)1.8 blocker to effectively reduce tactile allodynia in neuropathic rats further supports the role of Na(v)1.8 sodium channels in pathological pain states.
Neuropharmacology 09/2010; 59(3):201-7. · 4.81 Impact Factor
-
Marc J C Scanio,
Lei Shi,
Irene Drizin,
Robert J Gregg,
Robert N Atkinson,
James B Thomas,
Matthew S Johnson,
Mark L Chapman,
Dong Liu,
Michael J Krambis, [......],
Prisca Honore,
Kennan C Marsh,
Alison Knox,
Stephen Werness,
Brett Antonio,
Douglas S Krafte,
Michael F Jarvis, Connie R Faltynek,
Brian E Marron,
Michael E Kort
[show abstract]
[hide abstract]
ABSTRACT: Na(v)1.8 (also known as PN3) is a tetrodotoxin-resistant (TTx-r) voltage-gated sodium channel (VGSC) that is highly expressed on small diameter sensory neurons. It has been implicated in the pathophysiology of inflammatory and neuropathic pain, and we envisioned that selective blockade of Na(v)1.8 would be analgesic, while reducing adverse events typically associated with non-selective VGSC blocking therapeutic agents. Herein, we describe the preparation and characterization of a series of 6-aryl-2-pyrazinecarboxamides, which are potent blockers of the human Na(v)1.8 channel and also block TTx-r sodium currents in rat dorsal root ganglia (DRG) neurons. Selected derivatives display selectivity versus human Na(v)1.2. We further demonstrate that an example from this series is orally bioavailable and produces antinociceptive activity in vivo in a rodent model of neuropathic pain following oral administration.
Bioorganic & medicinal chemistry 09/2010; 18(22):7816-25. · 2.82 Impact Factor
-
Pamela S Puttfarcken,
Ping Han,
Shailen K Joshi,
Torben R Neelands,
Donna M Gauvin,
Scott J Baker,
La Geisha R Lewis,
Bruce R Bianchi,
Joseph P Mikusa,
John R Koenig,
Richard J Perner,
Michael E Kort,
Prisca Honore, Connie R Faltynek,
Philip R Kym,
Regina M Reilly
[show abstract]
[hide abstract]
ABSTRACT: The TRPV1 antagonist A-995662 demonstrates analgesic efficacy in monoiodoacetate-induced osteoarthritic (OA) pain in rat, and repeated dosing results in increased in vivo potency and a prolonged duration of action. To identify possible mechanism(s) underlying these observations, release of neuropeptides and the neurotransmitter glutamate from isolated spinal cord was measured. In OA rats, basal release of glutamate, bradykinin and calcitonin gene-related peptide (CGRP) was significantly elevated compared to naïve levels, whereas substance P (SP) levels were not changed. In vitro studies showed that capsaicin-evoked TRPV1-dependent CGRP release was 54.7+/-7.7% higher in OA, relative to levels measured for naïve rats, suggesting that TRPV1 activity was higher under OA conditions. The efficacy of A-995662 in OA corresponded with its ability to inhibit glutamate and CGRP release from the spinal cord. A single, fully efficacious dose of A-995662, 100 micromol/kg, reduced spinal glutamate and CGRP release, while a single sub-efficacious dose of A-995662 (25 micromol/kg) was ineffective. Multiple dosing with A-995662 increased the potency and duration of efficacy in OA rats. Changes in efficacy did not correlate with plasma concentrations of A-995662, but were accompanied with reductions in spinal glutamate release. These findings suggest that repeated dosing of TRPV1 antagonists enhances therapeutic potency and duration of action against OA pain, at least in part, by the sustained reduction in release of glutamate and CGRP from the spinal cord.
Pain 08/2010; 150(2):319-26. · 5.78 Impact Factor
-
Brian S Brown,
Ryan Keddy,
Richard J Perner,
Stanley DiDomenico,
John R Koenig,
Tammie K Jinkerson,
Steven M Hannick,
Heath A McDonald,
Bruce R Bianchi,
Prisca Honore,
Pamela S Puttfarcken,
Robert B Moreland,
Kennan C Marsh, Connie R Faltynek,
Chih-Hung Lee
[show abstract]
[hide abstract]
ABSTRACT: The synthesis and SAR of a series of indazole TRPV1 antagonists leading to the discovery of 21 (ABT-116) is described. Biological studies demonstrated potent in vitro and in vivo activity for 21, as well as suitable physicochemical and pharmacokinetic properties for advancement to clinical development for pain management.
Bioorganic & medicinal chemistry letters 06/2010; 20(11):3291-4. · 2.65 Impact Factor
-
Arturo Perez-Medrano,
Diana L. Donnelly-Roberts,
Prisca Honore,
Gin C. Hsieh,
Marian T. Namovic,
Sridhar Peddi,
Qi Shuai,
Ying Wang, Connie R. Faltynek,
Michael F. Jarvis,
William A. Carroll
[show abstract]
[hide abstract]
ABSTRACT: We disclose the design of a novel series of cyanoguanidines that are potent (IC50 10−100 nM) and selective (≥100-fold) P2X7 receptor antagonists against the other P2 receptor subtypes such as the P2Y2, P2X4, and P2X3. We also found that these P2X7 antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 μmol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X7 receptors in neuropathic pain and therefore a potential use of P2X7 antagonists as novel therapeutic tools for the treatment of this type of pain.
05/2009;
-
Arturo Perez-Medrano,
Diana L Donnelly-Roberts,
Prisca Honore,
Gin C Hsieh,
Marian T Namovic,
Sridhar Peddi,
Qi Shuai,
Ying Wang, Connie R Faltynek,
Michael F Jarvis,
William A Carroll
[show abstract]
[hide abstract]
ABSTRACT: We disclose the design of a novel series of cyanoguanidines that are potent (IC(50) approximately 10-100 nM) and selective (> or = 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED(50) of 38 micromol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.
Journal of Medicinal Chemistry 04/2009; 52(10):3366-76. · 4.80 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In order to enhance understanding of TRPV1 contributions to thermoregulation, we measured the effects of a TRPV1 receptor antagonist, A-889425, on thermoregulatory neurons in the medial preoptic area of the hypothalamus (mPOA) of rats while simultaneously monitoring rectal temperature (T(r)). Administration of A-889425 (4 micromol/kg, i.v.) significantly increased T(r) by 0.42+/-0.02 degrees C in anesthetized rats. Warm-sensitive (WS) neurons in the mPOA increase firing in response to body warming, and when active stimulate heat loss and inhibit heat production. WS neurons were initially inhibited by A-889425. Subsequently, WS neuronal activity diverged, differentiating WS neurons into two subgroups. One group of WS neurons continued to be inhibited during the recording period while another group of "biphasic" WS neurons increased firing as T(r) increased. Cold-sensitive (CS) neurons fire at a higher rate during cooling of the body, and when active, may contribute to heat production. Injection of A-889425 affected CS neurons in a manner opposite to the biphasic WS neurons; activity was initially increased followed by a later decrease. Direct administration of A-889425 into the mPOA (10 and 30 nmol) or spinal cord (30 nmol) did not affect T(r). Disruption of abdominal TRPV1 receptor function by injection of the TRPV1 receptor agonist, resiniferatoxin (20 microg/kg, i.p.), 9-15 days prior to experiments, blocked the effects of systemically injected A-889425 on T(r) and mPOA neuronal activity. These data demonstrate that antagonist block of abdominal TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the mPOA in a manner that is consistent with producing an acute rise in body temperature.
Brain research 03/2009; 1268:58-67. · 2.46 Impact Factor
-
Prisca Honore,
Prasant Chandran,
Gricelda Hernandez,
Donna M Gauvin,
Joseph P Mikusa,
Chengmin Zhong,
Shailen K Joshi,
Joseph R Ghilardi,
Molly A Sevcik,
Ryan M Fryer, [......],
Arthur Gomtsyan,
Chih-Hung Lee,
Michael E Kort,
Regina M Reilly,
Carol S Surowy,
Philip R Kym,
Patrick W Mantyh,
James P Sullivan,
Michael F Jarvis, Connie R Faltynek
[show abstract]
[hide abstract]
ABSTRACT: Transient receptor potential vanilloid type 1 (TRPV1) is a ligand-gated ion channel that functions as an integrator of multiple pain stimuli including heat, acid, capsaicin and a variety of putative endogenous lipid ligands. TRPV1 antagonists have been shown to decrease inflammatory pain in animal models and to produce limited hyperthermia at analgesic doses. Here, we report that ABT-102, which is a potent and selective TRPV1 antagonist, is effective in blocking nociception in rodent models of inflammatory, post-operative, osteoarthritic, and bone cancer pain. ABT-102 decreased both spontaneous pain behaviors and those evoked by thermal and mechanical stimuli in these models. Moreover, we have found that repeated administration of ABT-102 for 5-12 days increased its analgesic activity in models of post-operative, osteoarthritic, and bone cancer pain without an associated accumulation of ABT-102 concentration in plasma or brain. Similar effects were also observed with a structurally distinct TRPV1 antagonist, A-993610. Although a single dose of ABT-102 produced a self-limiting increase in core body temperature that remained in the normal range, the hyperthermic effects of ABT-102 effectively tolerated following twice-daily dosing for 2 days. Therefore, the present data demonstrate that, following repeated administration, the analgesic activity of TRPV1 receptor antagonists is enhanced, while the associated hyperthermic effects are attenuated. The analgesic efficacy of ABT-102 supports its advancement into clinical studies.
Pain 02/2009; 142(1-2):27-35. · 5.78 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: TRPV1 receptors are activated and/or modulated by noxious heat, capsaicin, protons and other endogenous agents released following tissue injury. There is a growing appreciation that this molecular integrator may also have a role in mechanosensation. To further understand this role, we investigated the systemic and site-specific effects of a selective TRPV1 receptor antagonist, A-889425, on low-intensity mechanical stimulation in inflamed rats. Systemic administration of A-889425 (30 and 100 micromol/kg po) reduced mechanical allodynia in complete Freund's adjuvant (CFA)-inflamed rats. Systemic A-889425 (3 and 10 micromol/kg iv) also decreased the responses of spinal wide dynamic range (WDR) neurons to low-intensity mechanical stimulation in CFA-inflamed but not uninjured rats. This effect of A-889425 was likely mediated via multiple sites since local injection of A-889425 into the spinal cord (1-3 nmol), ipsilateral hindpaw (200 nmol), and cerebral ventricles (30-300 nmol) all attenuated WDR responses to low-intensity mechanical stimulation. In addition to an effect on mechanotransmission, systemic administration of A-889425 reduced the spontaneous firing of WDR neurons in inflamed but not uninjured rats. Spontaneous firing is elevated after injury and may reflect ongoing pain in the animal. Local injection experiments indicated that this effect of A-889425 on spontaneous firing was mainly mediated via TRPV1 receptors in the spinal cord. Thus the current data demonstrate that TRPV1 receptors have an enhanced role after an inflammatory injury, impacting both low-intensity mechanotransmission and possibly spontaneous pain. Furthermore this study delineates the differential contribution of central and peripheral TRPV1 receptors to affect spontaneous or mechanically evoked firing of WDR neurons.
Journal of Neurophysiology 11/2008; 100(6):3158-66. · 3.32 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: 1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea (A-425619), a novel, potent, and selective transient receptor potential type V1 (TRPV1) antagonist, attenuates pain associated with inflammation and tissue injury in rats. The purpose of this study was to extend the in vitro characterization of A-425619 to native TRPV1 receptors and to compare the pharmacological properties of TRPV1 receptors in the dorsal root ganglion with trigeminal ganglion neurons. A robust increase in intracellular Ca(2+) was elicited by a variety of TRPV1 agonists with similar rank order of potency between both cultures: resiniferatoxin>tinyatoxin>capsaicin>N-arachidonoyl-dopamine (NADA). A-425619 blocked the 500 nM capsaicin response in both dorsal root ganglion with trigeminal ganglion cultures with IC(50) values of 78 nM and 115 nM, respectively, whereas capsazepine was significantly less potent (dorsal root ganglia: IC(50)=2.63 microM; trigeminal ganglia: IC(50)=6.31 microM). Furthermore, A-425619 was more potent in blocking the 3 microM NADA-evoked response in both dorsal root ganglia (IC(50)=36 nM) and trigeminal ganglia (IC(50)=37 nM) than capsazepine (dorsal root ganglia, IC(50)=741 nM; trigeminal ganglia, IC(50)=708 nM). Electrophysiology studies showed that 100 nM A-425619 completely inhibited TRPV1-mediated acid activated currents in dorsal root ganglia and trigeminal ganglia neurons. In addition, A-425619 blocked capsaicin- and NADA-evoked calcitonin gene-related peptide (CGRP) release in both cultures more effectively than capsazepine. These data show that A-425619 is a potent TRPV1 antagonist at the native TRPV1 receptors, and suggest that the pharmacological profile for TRPV1 receptors on dorsal root ganglia and trigeminal ganglia is very similar.
European Journal of Pharmacology 09/2008; 596(1-3):62-9. · 2.52 Impact Factor
-
Brian S Brown,
Ryan Keddy,
Guo Zhu Zheng,
Robert G Schmidt,
John R Koenig,
Heath A McDonald,
Bruce R Bianchi,
Prisca Honore,
Michael F Jarvis,
Carol S Surowy,
James S Polakowski,
Kennan C Marsh, Connie R Faltynek,
Chih-Hung Lee
[show abstract]
[hide abstract]
ABSTRACT: A series of 1,2,3,6-tetrahydropyridyl-4-carboxamides, exemplified by 6, have been synthesized and evaluated for in vitro TRPV1 antagonist activity, and in vivo analgesic activity in animal pain models. The tetrahydropyridine 6 is a novel TRPV1 receptor antagonist that potently inhibits receptor-mediated Ca2+ influx in vitro induced by several agonists, including capsaicin, N-arachidonoyldopamine (NADA), and low pH. This compound penetrates the CNS and shows potent anti-nociceptive effects in a broad range of animal pain models upon oral dosing due in part to its ability to antagonize both central and peripheral TRPV1 receptors. The SAR leading to the discovery of 6 is presented in this report.
Bioorganic & medicinal chemistry 09/2008; 16(18):8516-25. · 2.82 Impact Factor
-
Irene Drizin,
Robert J Gregg,
Marc J C Scanio,
Lei Shi,
Michael F Gross,
Robert N Atkinson,
James B Thomas,
Matthew S Johnson,
William A Carroll,
Brian E Marron, [......],
Chang Z Zhu,
Shailen Joshi,
Prisca Honore,
Kennan C Marsh,
Rosemarie Roeloffs,
Stephen Werness,
Douglas S Krafte,
Michael F Jarvis, Connie R Faltynek,
Michael E Kort
[show abstract]
[hide abstract]
ABSTRACT: The synthesis and pharmacological characterization of a novel furan-based class of voltage-gated sodium channel blockers is reported. Compounds were evaluated for their ability to block the tetrodotoxin-resistant sodium channel Na(v)1.8 (PN3) as well as the Na(v)1.2 and Na(v)1.5 subtypes. Benchmark compounds from this series possessed enhanced potency, oral bioavailability, and robust efficacy in a rodent model of neuropathic pain, together with improved CNS and cardiovascular safety profiles compared to the clinically used sodium channel blockers mexiletine and lamotrigine.
Bioorganic & medicinal chemistry 07/2008; 16(12):6379-86. · 2.82 Impact Factor
-
Carol S Surowy,
Torben R Neelands,
Bruce R Bianchi,
Steve McGaraughty,
Rachid El Kouhen,
Ping Han,
Katharine L Chu,
Heath A McDonald,
Melissa Vos,
Wende Niforatos,
Erol K Bayburt,
Arthur Gomtsyan,
Chih-Hung Lee,
Prisca Honore,
James P Sullivan,
Michael F Jarvis, Connie R Faltynek
[show abstract]
[hide abstract]
ABSTRACT: The transient receptor potential vanilloid (TRPV) 1 receptor, a nonselective cation channel expressed on peripheral sensory neurons and in the central nervous system, plays a key role in pain. TRPV1 receptor antagonism is a promising approach for pain management. In this report, we describe the pharmacological and functional characteristics of a structurally novel TRPV1 antagonist, (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), which has entered clinical trials. At the recombinant human TRPV1 receptor ABT-102 potently (IC(50) = 5-7 nM) inhibits agonist (capsaicin, N-arachidonyl dopamine, anandamide, and proton)-evoked increases in intracellular Ca(2+) levels. ABT-102 also potently (IC(50) = 1-16 nM) inhibits capsaicin-evoked currents in rat dorsal root ganglion (DRG) neurons and currents evoked through activation of recombinant rat TRPV1 currents by capsaicin, protons, or heat. ABT-102 is a competitive antagonist (pA(2) = 8.344) of capsaicin-evoked increased intracellular Ca(2+) and shows high selectivity for blocking TRPV1 receptors over other TRP receptors and a range of other receptors, ion channels, and transporters. In functional studies, ABT-102 blocks capsaicin-evoked calcitonin gene-related peptide release from rat DRG neurons. Intraplantar administration of ABT-102 blocks heat-evoked firing of wide dynamic range and nociceptive-specific neurons in the spinal cord dorsal horn of the rat. This effect is enhanced in a rat model of inflammatory pain induced by administration of complete Freund's adjuvant. Therefore, ABT-102 potently blocks multiple modes of TRPV1 receptor activation and effectively attenuates downstream consequences of receptor activity. ABT-102 is a novel and selective TRPV1 antagonist with pharmacological and functional properties that support its advancement into clinical studies.
Journal of Pharmacology and Experimental Therapeutics 06/2008; 326(3):879-88. · 3.83 Impact Factor
-
Derek W Nelson,
Kathy Sarris,
Douglas M Kalvin,
Marian T Namovic,
George Grayson,
Diana L Donnelly-Roberts,
Richard Harris,
Prisca Honore,
Michael F Jarvis, Connie R Faltynek,
William A Carroll
[show abstract]
[hide abstract]
ABSTRACT: N'-aryl acyl hydrazides were identified as P2X7 receptor antagonists. Structure-activity relationship (SAR) studies evaluated functional activity by monitoring calcium flux inhibition in cell lines expressing recombinant human and rat P2X7 receptors. Selected analogs were assayed in vitro for their capacity to inhibit release of cytokine IL-1beta. Compounds with potent antagonist function were evaluated in vivo using the zymosan-induced peritonitis model. A representative compound effectively attenuated mechanical allodynia in a rat model of neuropathic pain.
Journal of Medicinal Chemistry 06/2008; 51(10):3030-4. · 5.25 Impact Factor
